Skip to main content
Mario Juruena

Dr Mario Juruena MD MSc Dip CBT MPhil PhD SARCPsych FBPsychA

Reader in Translational Psychiatry

  • Consultant Psychiatrist at South London and Maudsley NHS Foundation Trust
  • - Head, Maudsley Advanced Treatment (MATS)
  • - Lead Consultant Maudsley ECT Clinic, SLaM

Biography

Dr Mario Juruena commenced his academic journey at King’s College London by enrolling in a PhD program and undergoing enriching academic training at the Institute of Psychiatry, King’s College London, and the South London and Maudsley Trust (SLaM) from 2003 to 2008.

He currently holds the position of Reader in Translational Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience, Centre for Affective Disorders, Department of Psychological Medicine at King’s College London, UK.

Between 2009 and 2015, he held a substantive academic appointment as a Professor Doctor at the Deptartment of Neurosciences and Behaviour, Division of Psychiatry at the University of Sao Paulo.

Dr Juruena returned to the UK in 2015 after being awarded the Newton Research Fellowship from the Royal Society and Academy of Medical Sciences.

His expertise primarily focuses on Treatment-Resistant Affective Disorders such as Depression and Bipolar disorder. He explores biomarkers, particularly neuroendocrine factors, and their association with stress, childhood trauma, and cognitive impairment in treatment-resistant affective patients. Additionally, he conducts clinical trials for new targets in pharmacotherapy, neuroimaging and neuromodulation in affective disorders.

He graduated in Medicine (MD) from Pontifical Catholic University, Southern Brazil. Dr Juruena completed his Psychiatry Training at the Saint Peter Hospital/ Public Health School and received his MPhil in Psychobiology at the Federal University of Sao Paulo and then MSc in Affective Neuroscience at Maastricht University in the Netherlands. He has also completed Cognitive Psychotherapy Training at Beck Institute (Dip CBT), Philadelphia, USA.

Dr Juruena completed his PhD in Treatment-Resistant Depression and Stress Hormones at the University of London/King’s College London in 2007

Dr Juruena holds the position of adjunct professor in the Department of Psychiatry and Behavioral Sciences at McGovern Medical School, University of Texas Science Center in Houston, and is an Honorary Professor in the Department of Psychiatry at Federal University of Sao Paulo.

He has been honoured with awards such as 'The Senior Clinical Psychopharmacology Award' by the British Association for Psychopharmacology and the 'Robert W. Kerwin Psychopharmacology Prize' from the Royal College of Psychiatrists for the best article published on the subject in the British Journal of Psychiatry.

Research interests

The main focus of his research is diagnostic, biomarkers, psychopharmacology and psychoneuroendocrinology in Affective Disorders. Mainly Difficult to Treat Affective Disorders, looking to understand the aetiology, neurobiology and long-term outcome of Treatment-Resistant Depression, Resistant Bipolar, Post-Traumatic Stress Disorder, Treatment-Resistant Personality Disorders and relation to Early Life Stress.

Other research interests include: Clinical trials for new targets in pharmacotherapy, neuroimaging and neuromodulation in affective disorders, including fMRI studies in depression and Bipolar investigating the neural correlates with separate symptom constructs – affective, behavioural and cognitive; the impact of early life trauma and the effects of pharmacotherapy on these brain networks; the effects of psychological therapy on these systems; and early neural markers of treatment response.

Contribution to the Field: Since his early career he has been studying the Hypothalamus-Pituitary-Adrenal (HPA) function and their modulation in Affective disorders. In his doctorate (PhD) from the University of London, it became more significant with the developing of a novel suppressive test for the HPA axis using prednisolone (Juruena et al. 2003, 2004, 2005, 2006, 2007, 2009, 2010, 2013).

For the first time, Dr Juruena et al. analysed the extent to which Mineralocorticoid Receptors (MR) contribute to HPA axis suppression in Treatment-Resistant Depressed (TRD) patients. It has become more significant with the developing of a novel suppressive test for the HPA axis using prednisolone (Juruena et al. 2006, 2007, 2009, 2010, 2013, 2015, 2018, 2018). Additionally, his studies found a marked hypercortisolism in TRD sufficiently severe to require inpatient treatment and was able to link the MR function prospectively at the baseline to the long-term therapeutic response to the antidepressant treatment in a prospective component of the study in TRD patients. 

Research Groups

Research Projects

  • Oral Ketamine
  • EDEN Project: a randomised study to investigate the pharmacokinetics and pharmacodynamics including safety, tolerability, metabolism and comparable bioavailability of oral ketamine in capsule delivery formulations versus IV ketamine, in healthy volunteers. 

Teaching

Expertise and Public Engagement

  • Royal College of Psychiatrists - UK
  • GMC Specialist Register Specialty: General Adult Psychiatry
  • London Region Section 12/AC Panel S12/AC approval
  • CCST by Specialist Training Authority - Medical Royal Colleges
  • British Association for Psychopharmacology
  • British Medical Association
  • European Psychiatric Association
  • European College of Neuropsychopharmacology
  • Brazilian Psychiatry Association
  • American Psychiatry Association, USA
  • National Affective Disorder Service, Maudsley Advance treatment Service (MATS), and Maudsley Hospital ECT Clinic - link to profile
  • Bipolar Disorder: From Neuroscience to Treatment - link to book
  • The complexities of bipolar disorder with Dr Mario Juruena - link to podcast
  • GlobePerson Beyond Mental Health Borders: Mario Juruena -  link to interview

Publications

Dr Juruena has published over 150 original research articles, reviews and book chapters, and edited five books. He has approximately 600 abstracts published in more than 750 meeting presentations. H-Index = 42; >8370 citations; >4500 citations in the last 5 years (Apr 2024).

The vast majority of his studies are related to the neurobiology, diagnostic, pathophysiology, and therapeutics of Affective Disorders (Depression, Bipolar, Anxiety, PTSD), including Treatment-Resistant, Psychopharmacology (antidepressants, mood stabilizers, atypical antipsychotics, new drugs, clinical trials), Psychoneuroendocrinology (HPA axis, Stress), Neuromodulation and their approach to Mental Health. See details on the publications tab below, or at the following links:

https://kclpure.kcl.ac.uk/portal/mario.juruena.html

https://scholar.google.com/citations?hl=en&user=Co4_RtYAAAAJ&view_op=list_works

    Research

    MNT logo
    Maudsley Neurotechnology (MNT)

    Maudsley Neurotechnology is a clinical and academic centre for evaluating and delivering evidence-based neurotechnology treatments for mental health disorders

    CFIT_Resize_780x440
    Oral Ketamine

    Oral ketamine project facilitated by C-FIT

    Project status: Ongoing

    Centre for Neuroimaging
    Ketamine Research

    Using brain imaging techniques, we will observe the effects of ketamine treatment on brain activity patterns and how this relates to any changes in the symptoms of treatment resistant depression.

    brain trees
    Centre for Affective Disorders (CfAD)

    The Centre for Affective Disorders (CfAD) focuses on mood and anxiety disorders, common disorders which cause great suffering for many people.

    News

    £1.45million awarded for EDEN Project, a trial exploring ketamine for depression with anorexia nervosa

    King’s researchers have been awarded the funds the MRC Developmental Pathway Funding Scheme to run a randomised controlled feasibility trial of oral ketamine...

    Someone talking to a professional

      Research

      MNT logo
      Maudsley Neurotechnology (MNT)

      Maudsley Neurotechnology is a clinical and academic centre for evaluating and delivering evidence-based neurotechnology treatments for mental health disorders

      CFIT_Resize_780x440
      Oral Ketamine

      Oral ketamine project facilitated by C-FIT

      Project status: Ongoing

      Centre for Neuroimaging
      Ketamine Research

      Using brain imaging techniques, we will observe the effects of ketamine treatment on brain activity patterns and how this relates to any changes in the symptoms of treatment resistant depression.

      brain trees
      Centre for Affective Disorders (CfAD)

      The Centre for Affective Disorders (CfAD) focuses on mood and anxiety disorders, common disorders which cause great suffering for many people.

      News

      £1.45million awarded for EDEN Project, a trial exploring ketamine for depression with anorexia nervosa

      King’s researchers have been awarded the funds the MRC Developmental Pathway Funding Scheme to run a randomised controlled feasibility trial of oral ketamine...

      Someone talking to a professional